Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Release pattern" patented technology

A smart drug-loaded unit with graded response and a controlled release system thereof

The application discloses a kind of hierarchical response intelligent drug-loading units and its controlled-release system, including A type drug-loading microbubble and B type phase change droplet, A type drug-loading microbubble includes gas core and rigid shell, the first drug active substance is loaded in the rigid shell, and the A type drug-loading microbubble has first burst threshold;B type phase change droplet includes low-boiling liquid perfluorocarbon core and phospholipid shell, the second drug active substance is loaded in the phospholipid shell, and the B type phase change droplet has phase transition threshold and second burst threshold;Wherein, first burst threshold>Second burst threshold>Phase transition threshold.The application realizes the precision and intelligent controlled-release of drug, significantly improves curative effect and reduces toxic side effect, benefits from the core structure design of hierarchical response drug-loading unit and programmable ultrasonic excitation sequence, and the application completely changes the extensive release mode of traditional one-time blasting.
Owner:TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL

Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders

The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns:a) a first part, G1, comprising from about 5 to about 70% w / w of the total dose of acarbose,b) a second part, G2A, comprising from about 30 to about 95% w / w of the total dose of acarbose,c) a third part, G2B, comprising from about 10 to about 90% w / w of the total dose of orlistat, andd) a fourth part, G3, comprising from about 10 to about 80% w / w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w / w.
Owner:EMPROS PHARMA AB